Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HIV multiantigen vaccine - Bavarian Nordic

Drug Profile

HIV multiantigen vaccine - Bavarian Nordic

Alternative Names: 2E8 TCID50 MVA-mBN120B - Bavarian Nordic; MVA-BN HIV multiantigen; MVA-HIV multiantigen vaccine MVA-mBN120B - Bavarian Nordic; MVA-mBN120B

Latest Information Update: 29 Sep 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bavarian Nordic
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - HIV-1 infections

Highest Development Phases

  • Discontinued HIV-1 infections

Most Recent Events

  • 29 May 2008 Phase-I/II clinical trials in HIV-1 infections in USA (SC)
  • 29 Apr 2008 Preclinical trials in HIV-1 infections in USA (Parenteral)
  • 29 Apr 2008 Bavarian Nordic files an IND application with the USA FDA to begin a phase I/II trial for treatment of HIV-1 infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top